CD274 and melanoma: These studies revealed that melanoma patients with negative expression of PD-L1 in the tumors also displayed objective responses to nivolumab in a Phase I clinical study[35] and no relationships were found between positive expression of PD-L1 improved responses to nivolumab and ipilimumab in another Phase I clinical trials [36].